ReviewNature reviews. Microbiology2018
Engineering bacteria for diagnostic and therapeutic applications.
Review in Nature reviews. Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
214 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Engineered bacteria and engineered probiotics for intestinal disease therapy: a bibliometric and knowledge mapping analysis.Frontiers in microbiology · 2026Pooled it
- Genome-integrated engineering ofSynthetic and systems biotechnology · 2027Article
- Synthetic biology of oncolytic bacteria: Comparative microbial chassis and precise killing strategies.Toxicology reports · 2026Review
- Sonogenetic Control of Engineered Probiotics for the Treatment of MASH by Modulating the Gut-Liver Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Microbiome-Derived Metabolic Signaling in the Gut-Skin Axis: Implications for Nutricosmetics and Healthy Skin Aging.Nutrients · 2026Review
- Systems engineering of engineered live biotherapeutics: A discovery-to-translation framework for streamlining microbiome therapeutic development.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- An engineered bacterial symbiont maps micron-scale sugar gradients in the honeybee gut.PLoS biology · 2026Article
- Lactobacillus-Loaded Bioadhesive Hydrogel with Prolonged Retention and Microenvironmental Remodeling for Endometrial Repair and Fertility Restoration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineered Bacteroides thetaiotaomicron sense gut inflammation and deliver therapeutic molecules to alleviate colitis in mice.Nature microbiology · 2026Article
- Single-Step Chromosomal Engineering Integrates Biocontainment and Therapeutic Function for Regulatory-Oriented Live Biotherapeutic Chassis Design.Pharmaceutics · 2026Article
- Bioinspired microcapsule reactor with engineered probiotics for IBD therapy.Nature communications · 2026Article
- Engineered probiotics platform for resolvin E1 biosynthesis confers protection against inflammatory disease.Clinical and translational medicine · 2026Article
- Engineering the microbiome: A novel frontier in inflammatory bowel disease treatment.Chinese medical journal · 2026Article
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- The Use of Bacteria and Their Toxins as Antitumor Agents: Present and Future.Microorganisms · 2026Review
- Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives.Protein & cell · 2026Review
- Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Engineering smart bacteria for the next generation.Cell reports. Medicine · 2026Review
- Associate toxin-antitoxin with CRISPR-Cas to harness (ATTACH) engineered microbes.Nucleic acids research · 2026Article
- Preclinical Evaluation of Synthetic Biology-Driven EngineeredACS synthetic biology · 2026Article
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our ability to generate bacterial strains with unique and increasingly complex functions has rapidly expanded in recent times. The capacity for DNA synthesis is increasing and costing less; new tools are being developed for fast, large-scale genetic manipulation; and more tested genetic parts are available for use, as is the knowledge of how to use them effectively. These advances promise to unlock an exciting array of 'smart' bacteria for clinical use but will also challenge scientists to better optimize preclinical testing regimes for early identification and validation of promising strains and strategies. Here, we review recent advances in the development and testing of engineered bacterial diagnostics and therapeutics. We highlight new technologies that will assist the development of more complex, robust and reliable engineered bacteria for future clinical applications, and we discuss approaches to more efficiently evaluate engineered strains throughout their preclinical development.
Indexed as
Identifiers
29398705What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.